8712 Stäfa, ch
+41 (58) 92833-44
Sonova on course - Further growth in sales and earnings
- Group sales of CHF 1,795.3 million were up 10.8% in Swiss francs and 7.4% in local currencies
- Reported EBITA of CHF 182.8 million fully accounts for one-off costs, mainly related to a provision increase to cover potential liabilities in the wake of a 2006 product recall by Advanced Bionics, more than three years prior to its acquisition by Sonova in 2009
- Normalized for one-off costs*, EBITA was CHF 386.4 million or 21.5% of sales, up 22.6% in Swiss francs and 15.4% in local currencies
- The hearing instruments segment reported sales of CHF 1,648.5 million, up 4.9% in local currencies
- The cochlear implants segment reached its break-even target on a normalized basis*, supported by sales of CHF 146.7 million, up 47.1% in local currencies
- The operating free cash flow rose by 33.0% to CHF 318.6 million
- The Board of Directors proposes a dividend increase of 33% to CHF 1.60 per share
- Outlook: for FY 2013/14, sales are anticipated to grow by 6% to 8% and EBITA to rise by 9% to 13%, both measured in local currencies and on a normalized basis*
Commenting on the results, Lukas Braunschweiler, CEO of Sonova said: ”The very solid accomplishments of this financial year demonstrate once again the benefit of our broad hearing solutions portfolio. In a challenging market environment, both segments significantly contributed to the top-line growth. The sound performance in the Asia/Pacific region in part reflects the considerable potential of the fast-growing emerging markets, which we continue to explore through targeted strategic initiatives. With a record number of new products announced and our continued commitment to innovation, Sonova is well on track to further achieve consistent growth in sales and earnings.”
New sales record achieved
The Sonova Group achieved another sales record in the year under review. Group sales rose 10.8% in Swiss francs and 7.4% in local currencies to CHF 1,795.3 million. The majority of the increase came from organic growth, which reached 5.2% in local currencies. External growth for 2012/13 represented around CHF 35.3 million or 2.2% of Group sales. Favorable currency development contributed CHF 56.0 million to reported sales, adding 3.4% to the growth rate in Swiss francs.
Growth reflects broad global footprint
All major regions achieved a solid sales increase. Sales in the EMEA region (Europe, Middle-East and Africa), which accounted for 40% of Group sales, rose by 5.3% in local currencies. US sales rose by 6.8% in local currencies and accounted for 37% of Group sales for the year. A strong performance in Canada and Brazil lifted growth in the rest of the Americas (excluding the USA) to 7.8% in local currencies. In the Asia/Pacific region, which contributed 11% to Group sales in the year under review, sales rose by 17.7% in local currencies.
Reported results impacted by one-off costs
The reported results were impacted by one-off costs of CHF 203.6 million included under other operating expenses. The main item is a cochlear implant product liability provision increase of CHF 197.8 million in the context of a first-instance verdict rendered in April 2013 by a US District Court in Kentucky, in a case related to Advanced Bionics’ Vendor B product recall in 2006. Further one-off charges include a restructuring provision for the reorganization of Advanced Bionics’ international distribution center in Rixheim, France, and the amount paid last October in connection with the out-of-court settlement with a group of investors related to the delayed profit warning in March 2011. All three cost items represent one-off costs that are excluded from discussion of normalized values referred to in this media release.
Solid margin improvement
Gross profit reached CHF 1,240.1 million, corresponding to a gross margin of 69.1%, an 80 basis points increase over the prior year, including 30 basis points from positive currency effects. Sales and marketing costs rose by 11.0% in Swiss francs or 8.0% in local currencies, representing 31.1% of sales, unchanged from the prior year. R&D costs as charged to the income statement for 2012/13 amounted to CHF 113.5 million, or 6.3% of sales. Despite our further global expansion, general and administrative expenses rose less than sales, by 7.5% in Swiss francs or 5.4% in local currencies, dropping to 10.1% of sales and reflecting controlled cost management during the financial year.
The reported operating profit before acquisition-related amortization and impairments (EBITA), which includes the one-off charges represented in other expenses, was CHF 182.8 million. Normalized EBITA* was CHF 386.4 million, strongly increasing by 22.6% in Swiss francs or 15.4% in local currencies. Favorable currency development contributed CHF 22.7 million to the rise in normalized EBITA* in Swiss francs. The normalized EBITA* margin expanded significantly by 200 basis points to 21.5% of sales. Normalized income after taxes* was CHF 308.9 million, up 25.4% from the previous year. Normalized basic earnings per share* (EPS) therefore reached CHF 4.62, a strong rise of 24.5% over the previous year.
Hearing instruments segment: consolidating our market leading position
The hearing instruments segment achieved sales of CHF 1,648.5 million in financial year 2012/13, which represents a growth rate of 8.2% in Swiss francs and 4.9% in local currencies. Organic growth accounted for 2.6% of the increase, a figure above the growth rate of the overall global market. Acquisitions added 2.3% to the reported growth rate. Supported by the successful launch of the well-received Phonak Quest platform in October 2012 and by the sustained strong performance of our Unitron brand, growth accelerated over the course of the year, despite an increasingly challenging market environment in Continental Europe. Innovation continued to be an important driver of growth: Sonova generated 70% of its hearing instrument revenue from products that have been on the market for less than two years. EBITA for the hearing instruments segment reached CHF 384.7 million, equivalent to an EBITA margin of 23.3%. EBITA rose by 13.4% in Swiss francs and by 6.7% in local currencies. At constant currency, the EBITA margin would have reached 22.6%, a 30 basis points improvement over the previous year.
Cochlear implants segment: break-even target reached
Normalized for one-off costs*, the performance of the cochlear implants segment was another highlight in the year under review. Sales rose to CHF 146.7 million, an increase of 52.3% in Swiss francs or 47.1% in local currencies. The business benefited from a full year of sales of its HiRes 90K implant following approval from the US Food and Drug Administration (FDA) in September 2011. The cochlear implants segment returned a normalized EBITA* of CHF 1.8 million, breaking even for the first time. The company also presented significant innovations during the year, including a new processor and a new electrode design that will generate profitable growth beyond 2012/13.
Strong free cash flow growth
Cash flow from operating activities rose by 27.0% to CHF 387.1 million in the year under review. The increase reflects the rise in normalized EBITA* of 22.6% and a favorable impact from working capital changes compared with the previous year. Investments in tangible and intangible assets reached CHF 82.3 million, up CHF 1.7 million, mainly as a result of higher capitalized development costs in the cochlear implants business. Operating free cash flow increased strongly by 33.0% to CHF 318.6 million. The cash consideration for acquisitions was CHF 56.2 million, including earn-out payments for prior period acquisitions, down from CHF 83.1 million in the prior year. This resulted in a free cash flow of CHF 262.4 million, up 67.7% from last year.
Increase in dividend proposed
Helped by strong cash flow development, the Sonova Group ended the year with a net cash position of CHF 185.8 million. The Board of Directors will propose to the 2013 AGM a substantially increased distribution of CHF 1.60 per share, payable without withholding taxes from the capital contribution reserves. This represents a significant increase of 33% compared to the prior financial year.
With our clear focus on driving profitable growth and our continued commitment to innovation, we aim to further expand and build on the strong market positions of Sonova. Despite a somewhat higher level of uncertainty regarding short-term market developments, we expect continued solid growth in sales and earnings in 2013/14, both in the hearing instruments and cochlear implants segment. Overall sales are anticipated to grow by 6% to 8% and EBITA to rise by 9% to 13% (both measured in local currencies and on a normalized basis*).
While actual reported results may vary based on currency fluctuations, Sonova continues to mitigate the impact of the strong Swiss franc on earnings growth through its long-term global resource allocation strategy. A strengthening of the US dollar by 5% would affect sales in the financial year by approximately CHF +38 million and EBITA by approximately CHF +11 million. The corresponding effect of a 5% stronger euro would be CHF +24 million on sales and CHF +12 million on EBITA.
The Annual Report 2012/13 is available on our website: http://www.sonova.com/en/investors/AnnualReports/Pages/default.aspx
The CSR report can be downloaded at: http://www.sonova.com/en/csrreport/
* Adjusted for one-off charges of CHF 203.6 million which consist of a product liability provision increase related to Advanced Bionics’ Vendor B product recall in 2006, a restructuring provision for the reorganization of the Advanced Bionics in France and the amount paid last October in connection with the out-of-court settlement with a group of investors related to the delayed profit warning in March 2011.
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Sonova’s control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sonova undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.